Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a promising biotechnology company with a strong focus on developing novel therapies for severe autoimmune and inflammatory disorders. Their lead drug candidate, EQ504, has shown positive results in clinical trials and has potential to treat other gastrointestinal conditions. However, potential challenges and competition in the market, as well as the need to raise funds, may hinder the company's success. Despite these potential obstacles, Equillium's innovative approach and potential for acquisition make it a positive investment opportunity.

Bears say

Equillium is showing potential in its development of EQ504 for the treatment of ulcerative colitis, with a promising reduction in calprotectin levels and a clinical trial for another drug on the horizon. However, concerns surrounding potential malignancy risks and the drug's Phase 1 results not expected until mid-2026 raise doubts about its potential success and overall impact on the company's financials. As a result, the financial analyst has a negative outlook on Equillium's stock due to the drug's uncertain future and limited immediate impact on the company's profitability.

Equillium Inc (EQ) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.